Chronic Myeloid Leukemia (eBook)

Rüdiger Hehlmann (Herausgeber)

eBook Download: PDF
2016 | 1st ed. 2016
X, 255 Seiten
Springer International Publishing (Verlag)
978-3-319-33198-0 (ISBN)

Lese- und Medienproben

Chronic Myeloid Leukemia -
Systemvoraussetzungen
117,69 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. 



Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany. Professor Hehlmann is past Chief of Medicine at Mannheim, past President of the German Society of Hematology and Oncology, past Dean of his faculty, and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is founder and chair of the German CML Study Group, of the German Competence Network on acute and chronic leukemias, and of the European LeukemiaNet. He is an honorary member of the Polish and German Societies for Hematology and honorary doctor of the University of Uppsala, Sweden. He has received various awards for leukemia research and interdisciplinary cooperation. His research interests focus on leukemia, in particular CML, on mechanisms of leukemogenesis, and on progression to blast crisis. 

Rüdiger Hehlmann is a Professor of Medicine at the Mannheim Medical Faculty of the University of Heidelberg, Germany. Professor Hehlmann is past Chief of Medicine at Mannheim, past President of the German Society of Hematology and Oncology, past Dean of his faculty, and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is founder and chair of the German CML Study Group, of the German Competence Network on acute and chronic leukemias, and of the European LeukemiaNet. He is an honorary member of the Polish and German Societies for Hematology and honorary doctor of the University of Uppsala, Sweden. He has received various awards for leukemia research and interdisciplinary cooperation. His research interests focus on leukemia, in particular CML, on mechanisms of leukemogenesis, and on progression to blast crisis. 

Cytogenetics of CML.- The biology and pathogenesis of CML.- The choice of 1st line CML‐treatment.- A review and up‐date of the European LeukemiaNet recommendations for the management of CML.- Management of adverse events associated with ATP‐competitive BCR‐ABL 1 tyrosine kinase inhibitors in CML.- Standardization of molecular monitoring for CML.- Epidemiology of CML.- Prognostic scores for patients with CML under particular consideration of disease specific death.- Response‐related predictors of survival.- CML‐ blast crisis: implications and management.- Chronic Myeloid Leukemia and Pregnancy.- The role of hematopoietic stem cell transplantation in CML.- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response.- The interferon‐alpha revival in CML.- Changing the cost of care for CML: the availability of generic imatinib.

Erscheint lt. Verlag 17.8.2016
Reihe/Serie Hematologic Malignancies
Zusatzinfo X, 255 p. 40 illus., 39 illus. in color.
Verlagsort Cham
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete
Schlagworte BCR-ABL • Chronic myeloid leukaemia • Deep molecular response • fertility • Health Economics • hematopoietic stem cell transplantation • Imatinib resistance • Interferon-alpha • Philadelphia chromosome • Survival • tyrosine kinase inhibitors
ISBN-10 3-319-33198-1 / 3319331981
ISBN-13 978-3-319-33198-0 / 9783319331980
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 8,0 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Hämatologie und Internistische Onkologie

von Dietmar P. Berger; Monika Engelhardt; Justus Duyster

eBook Download (2023)
Ecomed (Verlag)
99,99